Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo Sells 15,000 Shares

Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This trade represents a 24.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $128.61 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a market cap of $317.64 billion, a PE ratio of 102.89, a price-to-earnings-growth ratio of 5.53 and a beta of 0.19. The stock’s fifty day simple moving average is $123.98 and its two-hundred day simple moving average is $119.11. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Barclays lifted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. UBS Group lifted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. BMO Capital Markets upped their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Bank of America raised their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.56.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Institutional Trading of Merck & Co., Inc.

Several hedge funds and other institutional investors have recently modified their holdings of the business. D.A. Davidson & CO. boosted its holdings in Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after purchasing an additional 24,576 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 48.9% in the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after acquiring an additional 32,114 shares in the last quarter. Norris Perne & French LLP MI boosted its position in shares of Merck & Co., Inc. by 12.8% during the 4th quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock valued at $26,543,000 after acquiring an additional 28,635 shares during the last quarter. Pinnbrook Capital Management LP grew its holdings in shares of Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after purchasing an additional 11,355 shares in the last quarter. Finally, Cibc World Market Inc. increased its position in shares of Merck & Co., Inc. by 32.6% in the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after purchasing an additional 320,143 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.